- The FDA granted accelerated approval to Novartis AG's (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation.
- The patient must have progressed following prior therapy and have no alternative treatment options.
- The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer.
- Individuals as young as six years will be eligible to take the drug, making it the first BRAF/MEK inhibitor approved in pediatrics, Novartis said.
- Also Read: New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting.
- The FDA approval was based on clinical efficacy and safety demonstrated in three clinical trials, including a basket cancer trial that saw overall response rates reach as high as 80% in some tumors.
- Novartis tested the combo in tumors such as gliomas, biliary tract cancer, and gynecological and gastrointestinal cancers.
- Novartis said that the approval would likely give the use of the drug in over 20 different types of tumors.
- Price Action: NVS shares are down 0.10% at $81.59 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks